Skip to main content

Table 2 Baseline characteristics of patients with ankylosing spondylitis and rheumatoid arthritis

From: High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation

 

AS (n = 15)

RA (n = 17)

p-value

Age (years, mean ± SD)

32.9 ± 9.6

56.2 ± 10.4

<0.0001

Sex (male, n (%))

12 (80.0 %)

2 (11.8 %)

<0.0001

ESR (mm/h, mean ± SD)

53.7 ± 35.5

56.5 ± 31.3

NS

CRP (mg/dL, mean ± SD)

3.5 ± 3.5

2.9 ± 3.4

NS

Disease duration (years, mean ± SD)

5.2 ± 6.1

6.1 ± 6.3

NS

Eye involvement (n (%))

5 (33.3 %)

N/A

 

HLA-B27 positive (n (%))

13 (86.7 %)

N/A

 

BASDAI (mean ± SD)

4.3 ± 2.3

N/A

 

mSASSS (mean ± SD)

15.8 ± 16.7

N/A

 

Sacroiliitis grading (n (%))

 Grade 2

3 (20.0 %)

N/A

 

 Grade 3

9 (60.0 %)

N/A

 Grade 4

3 (20.0 %)

N/A

Current medications (n (%))

 MTX

7 (46.7 %)

14 (82.4 %)

0.062

 SSZ

8 (53.3 %)

1 (5.9 %)

0.005

 TNFi

3 (20 %)

1 (5.9 %)

0.319

 NSAID

13 (86.7 %)

16 (94.1 %)

0.589

  1. AS ankylosing spondylitis, BASDAI bath ankylosing spondylitis disease activity index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, MTX methotrexate, N/A not available, NS not significant, NSAID nonsteroidal anti-inflammatory drug, RA rheumatoid arthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor